HWVI 0.010    Updated: 04-18-2017 $HWVI Last Trade:

New Post Public Reply Private Reply Replies (0) Message Board
stockcharts
65
HWVI 0.010    Updated: 04-18-2017 $HWVI
Last Trade: 3/21/2017
Last 0.010   
Open 0.007
Previous Close 0.010
Day High / Low 0.010 / 0.007
Year High / Low - / -
Volume 30,000
Projected Volume 30000 (218%)
# of Trades / Projected 1 / -
Dividend / Yield - / -
Abnormal Activity NONE
Abnormal Volume NO
Gap NONE
Candle NEUTRAL
Volatility Today LOW
Volatility Yesterday LOW
Price Relativity
From 40 Day High 44%
From 80 Day High 44%
From 150 Day High 24%
From 40 Day Low 109%
From 80 Day Low 3167%
From 150 Day Low 3800%
Pivot Analysis
Price Pivot $ 0.020
Day Resistance 1 $ 0.020
Day Support 1 $ 0.020
Day Resistance 2 $ 0.020
Day Support 2 $ 0.020
Consolidations
Short Term YES
Medium Term YES
Long Term YES
Volume Indicators
20 Day Avg Vol 13,773
Today / 20 Day Avg Vol BELOW
150 Day Avg Vol 22,498
Today / 150 Day Avg Vol BELOW
Abnormal Volume NO
William Volume Accumulation bearish
Volume Price Trend bearish
Momentum Indicators
10 Day Trend bearish
40 Day Trend bearish
100 Day Trend bullish
Stochastics neutral
RSI neutral
MACD bearish
Moving Average Indictors
15 Day Trend bearish
45 Day Trend bullish
100 Day Trend bullish
Mid Term Moving Average Crossover NONE
Long Term Moving Average Crossover NONE
Volatility Indicators
Abnormal Activity Today? NONE
Volatility Index Today LOW
Volatility Index Yesterday LOW
10 Day Volatility DECREASING
20 Day Volatility DECREASING
40 Day Volatility DECREASING

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Halozyme's Upcoming Investment Presentation at Healthcare Conference

Updated Category News Views 280

Halozyme's Participation in Major Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) is set to showcase its advancements at an important healthcare conference. Dr. Helen Torley, the president and CEO, will present and engage in investor meetings, highlighting the company's innovative approaches in the biopharmaceutical sector. Details of the Presentation The...

Continue Reading
Emerging Markets Surge Ahead with Historic Bond Sales Strategy

Updated Category News Views 241

Emerging Markets Adjust with Record Bond Sales Amid economic uncertainty, borrowers in developing regions are intensifying their efforts to navigate potential market turbulence, particularly due to significant fluctuations influenced by US economic conditions. Authorities and businesses have proactively begun securing funds through bond sales, reflecting a strategic move...

Continue Reading
Multi Ways Holdings Reflects on Fiscal Year 2024 Performance

Updated Category News Views 167

Multi Ways Holdings Limited Reports on Financial Results Multi Ways Holdings Limited (NYSE American: MWG), a prominent provider of heavy construction equipment, has recently shared its financial outcomes for the fiscal year 2024. With a focus on innovation and customer satisfaction in Singapore and neighboring regions, the company continues to adapt to the dynamic market...

Continue Reading
Neurocrine Adjusts Course Following Luvadaxistat Study Setback

Updated Category News Views 117

Neurocrine Biosciences Shifts Strategy After Luvadaxistat Trial Neurocrine Biosciences Inc. (NASDAQ: NBIX) has made revisions to its strategic approach following the outcomes of the ERUDITE phase two clinical trial involving luvadaxistat (NBI-1065844). This investigational treatment aimed at addressing cognitive impairment in schizophrenia did not achieve its primary...

Continue Reading
Rinnai America Leads Coalition Against DOE Water Heater Rule

Updated Category News Views 294

Rinnai America Takes Action Against DOE Regulations Rinnai America Corporation, a prominent manufacturer of noncondensing tankless water heaters, has joined forces with 21 state attorneys general and various business groups to challenge the recent final rule issued by the U.S. Department of Energy (DOE) concerning consumer tankless water heaters. This action follows a...

Continue Reading